Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm

Pharmacy World and Science

Volumn 19, Issue 3, 1997, Pages 142-151

  Touw, D J ^a,b   Vinks, A A T M M ^c   Neef, C ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEYENBURG HOSPITAL   (Netherlands)

^c Central Hospital Pharmacy   (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Cystic fibrosis; Pharmacokinetics; Population modelling; Tobramycin

Indexed keywords

TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CYSTIC FIBROSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MAJOR CLINICAL STUDY;

ADOLESCENT; ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; CREATININE; CYSTIC FIBROSIS; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; SAMPLE SIZE; STATISTICS; STATISTICS, NONPARAMETRIC; TOBRAMYCIN;

EID: 0030752052     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008633526772     Document Type: Article

References (26)

1. Dodge WF Jelliffe RW, Richardson CJ, McCleery RA, Hokanson JA, Snodgrass WR. Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther 1991;50:25-31.
2. Eleveld EA, Neef C, Guchelaar HJ. Population pharmacokinetics of tobramycin [abstract]. Pharm World Sci 1995;17(Suppl M):8.
3. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospectice controlled study. J Pediatr 1984;105:117-24.
4. Horrevorts AM, Degener JE, Dzoljic-Danilovic G, Michel MF, Kerrebijn KF, Driessen O, et al. Pharmacokinetics of to bramycin in patients with cystic fibrosis: implications for the dosing interval. Chest 1985;88:260-4.
5. Touw DJ, Vinks AATMM, Heijerman HGM, Hermans J, Bakker W Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1994;16:125-31.
6. Touw DJ, Vinks AATMM, Jacobs F, Heijerman HGM, Bakker W. Creatinine clearance as predictor of tobramycin elimination constant in adult patients with cystic fibrosis. Ther Drug Monit 1996;18:562-9.
7. Steimer JL, Mallet A, Mentre F. Estimating interindividual pharmacokinetic variability. In: Rowland M, et al., editors. Variability in drug therapy: description, estimation, and control. New York: Raven Ress, 1985:65-109.
8. Beal S, Sheiner L. NONMEM Users guide - part 1: User's basic guide. Technical report of the division of clinical pharmacology, University of San Francisco, 1980.
9. Schumitzky A. Nonparametric EM algorithms for estimating prior distributions. Applied Mathematics and Computation 1991;45:143-57.
10. Jelliffe RW. User's manual for the PC programs from the USC Laboratory of Applied Pharmacokinetics. Los Angeles: University of Southern California School of Medicine, 1989.
11. Jelliffe RW, Schumitzky A, Van Guilder M. User manual for version 10.6 of the USC*PACK collection of PC programs. University of Southern California, 1995.
12. Touw DJ, Vinks AATMM, Heijerman HGM, Bakker W. Prospective evaluation of a dose-prediction algorithm for intravenous tobramycin in adolescent and adult patient with cystic fibrosis. Ther Drug Monit 1996; 18:118-23.
13. Jelliffe RW, Jelliffe SM. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex and weight. Math Biosci 1987;14:17-24.
14. Proost JH, Meijer DK, MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155-63.
15. Ng PK. Determining aminoglycoside dosage and blood levels using a programmable calculator. Am J Hosp Pharm 1980;37:225-31.
16. Dodge WF, Jelliffe RW, Richardson CJ, Bellanger RA, Hokanson JA, Snodgrass WR Population pharmacokinetic models: measures of central tendency. Drug Invest 1993;5:206-11.
17. Dodge WF, Jelliffe RW, Zwischenberger JB, Bellanger RA, Hokanson JA, Snodgrass WR Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994;16:552-9.
18. Buffington DE, Lampasona V Chandler MHH. Computers in pharmacokinetics. Choosing software for clinical decision making. Clin Pharmacokinet 1993;25:205-16.
19. Jelliffe RW, Schumitzky A, Van Guilder M. Nonpharmacokinetic clinical factors affecting aminoglycoside therapeutic precision. A simulation study. Drug Invest 1992;4:20-9.
20. Jelliffe RW. Explicit determination of laboratory assay error patterns. A useful aid in therapeutic drug monitoring. American Society of Clinical Pathologists Check Sample Continuing Education Program. Drug Monitoring and Toxicology No. DM-89-4, 1989.
21. Sheiner LB, Rosenberg B, Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm 1977;5:445-79.
22. Touw DJ, Vinks AATMM, Heijerman HGM, Bakker W. Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1993;15:52-9.
23. Vožeh S, Schmidlin O, Taeschner W. Pharmacokinetic drug data. Clin Pharmacokinet 1988;15:254-82.
24. Cameron JS. Renal function testing. In: Cameron S, Davidson AM, Grünfeld, Kerr D, Ritz E, editors. Oxford textbook of clinical nephrology. Vol 1. Oxford: Oxford University Press, 1992:24-49.
25. Hedman A, Adan-Abi Y, Alvan G, Strandvik B, Arvidsson A. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin Pharmacokinet. 1988;15:57-65.
26. Hedman A, Alvan G, Strandvik B, Arvidsson A. Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis. Clin Pharmacokinet 1990;18:168-75.